Stock Events

Stock Events

vTv Therapeutics 

€0.000000
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12AugExpected
Q1 2026
Next
-0.85
-0.1
0.66
1.41
Expected EPS
-0.8484299
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-23.33MNet Income

Analyst Ratings

38.19Average Price Target
The highest estimate is 44.01.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 5VT.STU. It's not an investment recommendation.
Tesla
7
TSLA
Palantir Technologies
7
PLTR
PayPal
7
PYPL
Amazon
6
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap31.91B
Biogen has a strong portfolio in neurodegenerative diseases, including Alzheimer's, making it a direct competitor to vTv Therapeutics.
Axsome Therapeutics
AXSM
Mkt Cap12.57B
Axsome Therapeutics works on central nervous system disorders, including Alzheimer's disease, competing in the same space as vTv Therapeutics.
AnaptysBio
ANAB
Mkt Cap1.88B
AnaptysBio is involved in developing therapeutic antibodies for inflammatory diseases, which could overlap with vTv Therapeutics' work on conditions like psoriasis.
Acadia Pharmaceuticals
ACAD
Mkt Cap4.45B
ACADIA Pharmaceuticals focuses on central nervous system disorders, posing competition to vTv Therapeutics' Alzheimer's disease treatments.
Alkermes
ALKS
Mkt Cap9.19B
Alkermes works on central nervous system diseases, including treatments for schizophrenia and bipolar I disorder, areas that could compete with vTv Therapeutics' focus.
AMGEN
AMGN
Mkt Cap201.93B
Amgen's broad focus on innovative therapeutics includes work on neurodegenerative diseases, making it a competitor in the Alzheimer's space.
Abbvie
ABBV
Mkt Cap461.26B
AbbVie has a diverse portfolio that includes neuroscience, directly competing with vTv Therapeutics in the Alzheimer's and cognitive impairment market.
Lilly(Eli) &
LLY
Mkt Cap1.08T
Eli Lilly has a strong presence in Alzheimer's disease research and treatment, directly competing with vTv Therapeutics.
Pfizer
PFE
Mkt Cap138.61B
Pfizer has a wide range of therapeutic areas, including Alzheimer's disease research, making it a competitor to vTv Therapeutics.

About

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
Show more...
CEO
Mr. Paul J. Sekhri
Employees
26
Country
United States
ISIN
US9183851057

Listings

STU
DE
5VT0.STU
MU
DE
5VT.MU
STU
DE
5VT.STU
MU
DE
5VT0.MU

0 Comments

Share your thoughts

FAQ

What is vTv Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange vTv Therapeutics stocks are traded under the ticker 5VT.STU.
When is the next vTv Therapeutics earnings date?▼
vTv Therapeutics is going to release the next earnings report on August 12, 2026.
What were vTv Therapeutics earnings last quarter?▼
5VT.STU earnings for the last quarter are 1.41 EUR per share, whereas the estimation was 0.18 EUR resulting in a +685.71% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is vTv Therapeutics revenue for the last year?▼
vTv Therapeutics revenue for the last year amounts to 0 EUR.
What is vTv Therapeutics net income for the last year?▼
5VT.STU net income for the last year is -23.33M EUR.
How many employees does vTv Therapeutics have?▼
As of July 10, 2026, the company has 26 employees.
In which sector is vTv Therapeutics located?▼
vTv Therapeutics operates in the Other sector.
When did vTv Therapeutics complete a stock split?▼
vTv Therapeutics has not had any recent stock splits.
Where is vTv Therapeutics headquartered?▼
vTv Therapeutics is headquartered in High Point, United States.